drugset / Trial / NCT03839693
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
RandomizedSequentialQuadruple-blindTreatment
Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Timeline
- Start
- 2018-10-16
- Primary completion
- 2019-04-18
- Completion
- 2019-09-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 345 iu | Topical |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 1100 iu | Topical |